ACB $1.670 (0%)

ACNNF $0.170 (-13.87%)

AERO $1.560 (0.32%)

AGEEF $0.115 (3.46%)

ALEAF $0.441 (-1.74%)

AMMJ $0.115 (0.35%)

APHA $4.140 (0%)

ARNA $52.690 (-1.01%)

ATT:CNX $0.080 (0%)

ATTBF $0.010 (9.27%)

AUSA:CNX $0.265 (-19.7%)

AUSAF $0.205 (-18.2%)

AVXL $5.090 (-1.36%)

BAMM:CNX $0.425 (-4.49%)

BBM:CNX $0.100 (0%)

BBRRF $0.080 (5.26%)

BE:CNX $0.030 (9.09%)

BIO:CNX $0.080 (0%)

BLEVF $0.020 (-33.33%)

BLO:CNX $0.640 (4.92%)

BLOZF $0.467 (3.55%)

BUDZ $0.307 (-3.97%)

BXNG $0.390 (21.84%)

CADMF $0.638 (6.3%)

CALI:CNX $0.090 (0%)

CANN $0.600 (-0.81%)

CARA $17.230 (0.17%)

CBII:CNX $0.120 (4.35%)

CBIIF $0.098 (8.89%)

CBWTF $0.429 (0.16%)

CGC $21.880 (0%)

CGRW $0.155 (-3.73%)

CHOO:CNX $0.140 (0%)

CHOOF $0.107 (-3.34%)

CNAB $0.132 (-5.31%)

CNBX $0.389 (-5.24%)

CNGGF $0.705 (-4.08%)

CODI $21.460 (0%)

CPMD $1.330 (0.76%)

CRBP $5.490 (-3.17%)

CRON $7.150 (-2.59%)

CRTPF $2.660 (-6.01%)

CRXPF $0.101 (6.21%)

CSI:CNX $0.900 (8.43%)

CTST $0.829 (0%)

CURR $2.360 (3.08%)

CVSI $0.870 (-1.15%)

DIGP $0.087 (7.47%)

DXBRF $0.155 (-1.59%)

EAPH $0.001 (-18.18%)

EAT:CNX $0.030 (-14.29%)

EEVVF $0.096 (-0.21%)

EMHTF $0.179 (-0.22%)

EPWCF $0.023 (-8.16%)

EVIO $0.063 (-3.38%)

FFRMF $0.026 (-11.86%)

FFT:CNX $0.040 (0%)

FNNZF $0.079 (0%)

GGTTF $0.115 (2.77%)

GLDFF $0.016 (-13.41%)

GLH:CNX $0.025 (25%)

GLNNF $0.140 (24.44%)

GNBT $0.620 (-1.59%)

GRIN:CNX $0.095 (5.56%)

GRWG $6.220 (-2.96%)

GSTR:CNX $0.060 (-7.69%)

GTBIF $8.580 (-3.08%)

GTII:CNX $11.320 (-3.66%)

GWPH $125.690 (-2.23%)

HEXO $1.410 (0%)

HHPHF $0.020 (0%)

HLSPY $0.540 (0%)

HMLSF $6.536 (-1.59%)

HMPPF $0.498 (0%)

HRVOF $0.071 (-8.9%)

HSTRF $0.120 (1.52%)

HUGE:CNX $7.830 (-1.14%)

IAN:CNX $1.580 (-5.95%)

IGC $0.575 (0%)

IGXT $0.405 (-1.17%)

IIPR $105.580 (0%)

IMLFF $0.250 (0%)

INQD $0.001 (0%)

IONC:CNX $0.020 (0%)

IONKF $0.015 (-20.63%)

ISOL:CNX $0.180 (0%)

ISOLF $0.148 (-0.2%)

ITHUF $1.210 (-4.7%)

IVITF $0.042 (7.97%)

JWCAF $0.146 (-6.54%)

KALTF $0.031 (3.33%)

KBEV:CNX $0.155 (6.9%)

KBEVF $0.115 (4.82%)

KHRNF $0.490 (-3.98%)

KSHB $1.360 (-2.86%)

LHS:CNX $0.650 (-5.8%)

LHSIF $0.500 (-4.3%)

LOVE:CNX $0.130 (0%)

LXLLF $0.380 (0%)

LXRP $0.480 (-2.04%)

LXX:CNX $0.630 (-3.08%)

MCIG $0.058 (-4.17%)

MDCL $2.330 (5.43%)

MEDIF $2.190 (-8.18%)

MGWFF $0.060 (-14.29%)

MICWF $0.035 (0.29%)

MJ:CNX $0.135 (0%)

MJNA $0.019 (-2.07%)

MNTR $0.125 (-3.85%)

MRRCF $0.008 (0.63%)

MWM:CNX $0.050 (0%)

MYM:CNX $0.085 (0%)

MYMMF $0.065 (-2.33%)

NCNNF $0.216 (-18.65%)

NDVAF $0.283 (-16.71%)

NGW:CNX $0.085 (0%)

NRXCF $0.044 (-3.24%)

NSPDF $0.047 (-1.46%)

NTEC $0.286 (2.11%)

NVTQF $0.161 (17.37%)

NWKRF $0.424 (0%)

NXGWF $0.070 (-0.07%)

NXTTF $0.356 (-1.41%)

ORHOF $4.050 (0%)

OWCP $0.043 (-6.83%)

PHGRF $0.336 (-1.12%)

PHVAF $0.093 (25.37%)

PILL:CNX $0.500 (0%)

PKG:CNX $0.100 (-9.09%)

PLPRF $0.812 (0.06%)

PLUS:CNX $1.070 (0%)

PMCB $0.054 (0.94%)

PNPL $0.690 (0%)

POTN $0.025 (-1.96%)

PRCNF $0.052 (-2.08%)

PTNYF $0.084 (-0.24%)

QCA:CNX $0.095 (0%)

RDDTF $0.271 (-0.95%)

RLLVF $0.017 (26.1%)

RMHB $0.036 (-0.28%)

RQB:CNX $0.040 (0%)

RQHTF $0.449 (1.75%)

RVVQF $0.032 (28.8%)

SLNG:CNX $0.315 (-3.08%)

SMG $120.660 (0%)

SNN:CNX $0.220 (-8.33%)

SNNVF $0.180 (-2.7%)

SOL:CNX $0.340 (17.24%)

SOLCF $0.256 (16.14%)

SPLIF $0.024 (-14.91%)

SPRWF $0.296 (-1.27%)

SRNA $0.069 (-1.43%)

STEM:CNX $1.200 (-0.83%)

STMH $0.910 (-1.09%)

SUN:CNX $0.175 (-5.41%)

TBPMF $0.294 (-7.26%)

TCAN:CNX $1.120 (12%)

TCNAF $0.803 (14.71%)

TER:CNX $2.950 (-1.99%)

TGEN $2.020 (-0.98%)

TGIF:CNX $0.175 (-5.41%)

TGIFF $0.135 (-3.57%)

THC:CNX $0.145 (0%)

THCBF $0.113 (5.41%)

TLRY $19.370 (0.68%)

TOKI:CNX $0.045 (0%)

TRLFF $0.107 (5.68%)

TRPX $0.491 (-1.78%)

TRSSF $2.280 (-0.87%)

TRTC $0.153 (-3.9%)

TURV $0.051 (20.24%)

VBIO $0.050 (0%)

VIDA:CNX $0.105 (0%)

VIN:CNX $0.015 (-25%)

VPRB $0.031 (28.01%)

VRNDF $0.448 (-2.53%)

VRT:CNX $0.120 (0%)

VRTHF $0.080 (-9.09%)

VVCIF $0.257 (-13.23%)

WAYL:CNX $0.740 (0%)

WDDMF $0.435 (-3.85%)

WLDFF $0.130 (-3.85%)

XXII $0.965 (0%)

ZDPY $0.206 (-5.37%)

ZYNE $4.920 (2.29%)

Technical420 Site Search

Returned 32 result(s).

3 Major European Cannabis Markets Investors Need To Be Watching

During the last year, we have seen a significant shift in the cannabis sector to where the market is considerably more focused on the international opportunity. Although Canada remains a great opportunity, the market is saturated, and distribution is limited. For this reason, we have seen a significant increase in…

3 Cannabis Stocks That Could Benefit From Feeling The Bern In 2020

Following Bernie Sanders’ victory in New Hampshire, we have received an influx of questions on the cannabis companies that would benefit from him being elected president of the United States. Bernie Sanders has previously stated that he would support the legal cannabis industry and highlighted plans to legalize the plant…

GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex

GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug…

5 Cannabis Stocks That Could Capitalize On The Booming EU Cannabis Sector

During the last year, the cannabis sector has been in the middle of a major transition that has been centered around the expansion into new markets. The European Union (EU) has been a point of emphasis for these cannabis operators and we are favorably on this strategy for growth. When…

5 Cannabis Stocks With Extremely Volatile Price Targets Movements

One of the most interesting trends that we have been following in the cannabis sector is related to the activity at the broker-dealer level. For the last few years, the broker dealers that have been focused on the cannabis industry have had it easy. On average, the sector was recording…

GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019

GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development and commercialization of cannabinoid prescription medicines, announces financial results for the second quarter ended June 30, 2019. “We are pleased to report a strong second quarter of sales of Epidiolex in the…

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome

GW Pharmaceuticals plc (Nasdaq: GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces positive top-line results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Dravet…

GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce the DEA has Rescheduled EPIDIOLEX® (cannabidiol) Oral Solution to Schedule V

GW Pharmaceuticals plc (GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S. Drug Enforcement…

GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome

GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for …

GW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of Directors

GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of three new independent members to its Board of Directors, bringing the GW Board to a total of eight members. Joining…

Older Posts »

Search Again